Is Padcev a subsidiary of Pfizer?

Padcev is a product brand, not a subsidiary. Pfizer owns Seagen's rights to it after acquiring Seagen in December 2023 for approximately $43 billion, and shares commercialization with Astellas under their collaboration.

Is Padcev publicly traded?

No. It is a drug brand. Owner Pfizer trades on the NYSE under ticker PFE; partner Astellas trades on the Tokyo Stock Exchange under 4503.

When was Padcev approved?

The FDA granted accelerated approval in December 2019 and regular approval in July 2021. The frontline combination with pembrolizumab was approved in December 2023.

Who developed Padcev?

Padcev was developed by Seagen (formerly Seattle Genetics) using its antibody-drug conjugate platform, co-developed and co-commercialized with Astellas Pharma.

What is Padcev's market position?

Padcev is the standard of care in metastatic urothelial cancer after its frontline combination approval, and one of the fastest-growing oncology products in Pfizer's portfolio.

Healthcare & Pharmaceuticals

Who Owns Padcev?

Padcev is owned by Pfizer Inc. (NYSE: PFE) in partnership with Astellas Pharma. Pfizer acquired rights through its December 2023 acquisition of Seagen for approximately $43 billion. Padcev (enfortumab vedotin) is an antibody-drug conjugate first FDA approved in December 2019 for urothelial bladder cancer and is co-commercialized with Astellas.

Parent Company

Pfizer Inc.

Acquired

2023

Status

Publicly Traded

Headquarters

Bothell, Washington, USA

Padcev Timeline

1849

Pfizer Inc.

Parent company established in New York, New York, USA

Company Founded

2019

Padcev

Founded by Seagen Inc. (original development), Astellas Pharma (co-developer)

Founded

2023

Acquired by Pfizer Inc.

Pfizer Inc. acquired Padcev

Acquired

GlobalOfficial Website

Who Owns Padcev?

Parent Company: Pfizer Inc.
Ownership Type: Subsidiary
Acquisition Year: 2023
Company Type: Publicly Traded
Stock Ticker: NYSE: PFE

Brand	Parent Company	Ownership Type
Padcev	Pfizer Inc.	Subsidiary

Where to Buy

Disclosure: We may earn commission from purchases

Padcev on Amazon

History of Padcev

Founded: 2019
Founders: Seagen Inc. (original development), Astellas Pharma (co-developer)
Acquired by Pfizer Inc.: 2023

Enfortumab vedotin was developed by Seattle Genetics using its proprietary antibody-drug conjugate technology: a monoclonal antibody targeting Nectin-4, a protein highly expressed on urothelial cancer cells, linked to the cytotoxic payload monomethyl auristatin E. The design delivers the toxic payload directly into cancer cells that express the target.

Astellas joined as partner during development, sharing costs and gaining co-commercialization rights. The FDA granted accelerated approval on December 18, 2019, for patients with locally advanced or metastatic urothelial cancer who had received prior platinum chemotherapy and immunotherapy, a population with few remaining options.

Regular approval followed in July 2021 after confirmatory trials. The transformative moment came with the combination of Padcev plus pembrolizumab (Keytruda), which demonstrated dramatic survival improvements over chemotherapy in first-line metastatic disease. The FDA approved the combination in December 2023 for first-line use, effectively repositioning Padcev from a salvage therapy into the backbone of frontline bladder cancer treatment.

That data arrived the same month Pfizer closed its $43 billion Seagen acquisition, validating the deal's central thesis: antibody-drug conjugates as a platform technology with major oncology franchises. Padcev revenue accelerated rapidly on the frontline expansion and crossed the billion-dollar annual threshold, becoming one of the fastest-growing products in Pfizer's oncology book through FY2025.

About Pfizer Inc.

What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.

Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.

Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.

Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.

How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.

Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.

What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.

Founded: 1849
Headquarters: New York, New York, USA
Company Type: Publicly Traded
Stock: NYSE: PFE
Revenue: $62.6 billion (FY2025)
Employees: approximately 88,000

Visit Pfizer Inc. website

View full company profile for Pfizer Inc.

Where Is Padcev Made / Based?

Headquarters: Bothell, Washington, USA
Manufacturing / Operations: United States, Japan

Padcev Categories & Tags

Oncology Bladder Cancer Antibody Drug Conjugate Prescription Drug Cancer Treatment

Padcev Recalls & Controversies

Padcev carries a boxed warning for severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, serious and sometimes fatal events that occurred in a small percentage of trial patients. The label requires close skin monitoring and dose interruption criteria, a toxicity profile oncologists weigh against its survival benefit.

Peripheral neuropathy and hyperglycemia are the other significant labeled toxicities, managed through monitoring and dose adjustment. Post-marketing surveillance continues under the FDA's standard requirements for oncology products.

No market withdrawal or recall has occurred. The drug's pricing, in the tens of thousands of dollars per treatment course, is subject to the same oncology cost scrutiny applied across the category, compounded now by its use in combination with pembrolizumab, which adds the cost of a second high-priced therapy.

Padcev Ownership: Pros & Cons

Advantages

+Frontline combination with pembrolizumab made Padcev standard of care in metastatic bladder cancer
+Seagen acquisition gave Pfizer the leading commercial ADC platform
+Revenue trajectory has been steep since frontline approval, crossing the blockbuster threshold
+Pfizer's global infrastructure accelerates market access beyond Seagen's standalone reach

Considerations

-Profit sharing with Astellas limits Pfizer's retention of collaboration-territory revenue
-Boxed warning for severe skin toxicity requires active management and deters some prescribing
-ADC competition is intensifying as multiple companies field programs in urothelial cancer
-Manufacturing complexity of ADCs limits supply-chain flexibility

Frequently Asked Questions About Padcev

Sources & Further Reading

Competitors to Padcev

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
AdcetrisSister Brand	Pfizer	United States	2011	Mass market	North america	All Genders
Opdivo	Bristol Myers Squibb	USA	2014	Mass market	Global	All Genders
IbranceSister Brand	Pfizer	USA	2015	Mass market	Global	All Genders
TukysaSister Brand	Pfizer	USA	2020	Mass market	Global	All Genders
XtandiSister Brand	Pfizer	USA	2012	Mass market	Global	All Genders
Afinitor	Novartis	Switzerland	2009	Mass market	North america	All Genders